Management of hemophilias - Gene therapy to come?

Z. Vajó, Lidia Sréter

Research output: Contribution to journalArticle

Abstract

Background: Hemophilias are relatively common coagulopathies that requíre very careful management to prevent bleeding and related complications. Objective: To review the current management of hemophilias, with an overview of gene therapy. Although with the availability of highly purified and recombinant factor concentrates the replacement therapy of hemophilias has become safer and more effective, a therapeutic method providing continuous supply of clotting factors is desirable. Theoretically, this is possible, by transplanting organs, than can express antihemophilic proteins, but in most cases a less invasive method is preferable. Therefore the gene therapy would be revolutionary in treating hemophiliacs. Conclusion: The treatment of choice for hemophilias is the infusion of highly purified or recombinant factor products. Although still in experimental level, gene therapy for hemophilias is promising and may become the treatment of choice in these disorders.

Original languageEnglish
Pages (from-to)191-198
Number of pages8
JournalActa Physiologica Hungarica
Volume84
Issue number2
Publication statusPublished - 1996

Fingerprint

Genetic Therapy
Blood Coagulation Factors
Therapeutics
Hemorrhage
Proteins

Keywords

  • Gen therapy
  • Hemophilia

ASJC Scopus subject areas

  • Physiology

Cite this

Management of hemophilias - Gene therapy to come? / Vajó, Z.; Sréter, Lidia.

In: Acta Physiologica Hungarica, Vol. 84, No. 2, 1996, p. 191-198.

Research output: Contribution to journalArticle

Vajó, Z. ; Sréter, Lidia. / Management of hemophilias - Gene therapy to come?. In: Acta Physiologica Hungarica. 1996 ; Vol. 84, No. 2. pp. 191-198.
@article{dbb23e7f5a964cd4ae45309618595e53,
title = "Management of hemophilias - Gene therapy to come?",
abstract = "Background: Hemophilias are relatively common coagulopathies that requ{\'i}re very careful management to prevent bleeding and related complications. Objective: To review the current management of hemophilias, with an overview of gene therapy. Although with the availability of highly purified and recombinant factor concentrates the replacement therapy of hemophilias has become safer and more effective, a therapeutic method providing continuous supply of clotting factors is desirable. Theoretically, this is possible, by transplanting organs, than can express antihemophilic proteins, but in most cases a less invasive method is preferable. Therefore the gene therapy would be revolutionary in treating hemophiliacs. Conclusion: The treatment of choice for hemophilias is the infusion of highly purified or recombinant factor products. Although still in experimental level, gene therapy for hemophilias is promising and may become the treatment of choice in these disorders.",
keywords = "Gen therapy, Hemophilia",
author = "Z. Vaj{\'o} and Lidia Sr{\'e}ter",
year = "1996",
language = "English",
volume = "84",
pages = "191--198",
journal = "Physiology International",
issn = "2498-602X",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Management of hemophilias - Gene therapy to come?

AU - Vajó, Z.

AU - Sréter, Lidia

PY - 1996

Y1 - 1996

N2 - Background: Hemophilias are relatively common coagulopathies that requíre very careful management to prevent bleeding and related complications. Objective: To review the current management of hemophilias, with an overview of gene therapy. Although with the availability of highly purified and recombinant factor concentrates the replacement therapy of hemophilias has become safer and more effective, a therapeutic method providing continuous supply of clotting factors is desirable. Theoretically, this is possible, by transplanting organs, than can express antihemophilic proteins, but in most cases a less invasive method is preferable. Therefore the gene therapy would be revolutionary in treating hemophiliacs. Conclusion: The treatment of choice for hemophilias is the infusion of highly purified or recombinant factor products. Although still in experimental level, gene therapy for hemophilias is promising and may become the treatment of choice in these disorders.

AB - Background: Hemophilias are relatively common coagulopathies that requíre very careful management to prevent bleeding and related complications. Objective: To review the current management of hemophilias, with an overview of gene therapy. Although with the availability of highly purified and recombinant factor concentrates the replacement therapy of hemophilias has become safer and more effective, a therapeutic method providing continuous supply of clotting factors is desirable. Theoretically, this is possible, by transplanting organs, than can express antihemophilic proteins, but in most cases a less invasive method is preferable. Therefore the gene therapy would be revolutionary in treating hemophiliacs. Conclusion: The treatment of choice for hemophilias is the infusion of highly purified or recombinant factor products. Although still in experimental level, gene therapy for hemophilias is promising and may become the treatment of choice in these disorders.

KW - Gen therapy

KW - Hemophilia

UR - http://www.scopus.com/inward/record.url?scp=0030338191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030338191&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 191

EP - 198

JO - Physiology International

JF - Physiology International

SN - 2498-602X

IS - 2

ER -